(Q34258563)

31 July 2017

1 reference

title

Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors (English)

1 reference

31 July 2017

0 references

Galanis E

1

1 reference

PubMed ID

11369253

31 July 2017

Vile R

series ordinal

2

1 reference

PubMed ID

11369253

31 July 2017

Russell SJ

series ordinal

3

1 reference

31 July 2017

1 June 2001

1 reference

Critical Reviews in Oncology Hematology

31 July 2017

1 reference

31 July 2017

38

1 reference

31 July 2017

177-192

1 reference

31 July 2017

3

1 reference

31 July 2017

Gene therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Gene therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

1 reference

7 January 2021

Gene therapy for cancer: what have we done and where are we going?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

1 reference

7 January 2021

Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Tissue-specific targeting of retroviral vectors through ligand-receptor interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Ligand-directed retroviral targeting of human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Retroviral retargeting by envelopes expressing an N-terminal binding domain.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Towards efficient cell targeting by recombinant retroviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Retroviral vectors displaying functional antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

A gene delivery system activatable by disease-associated matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine le

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Molecular biology of cell nonpermissiveness to retroviruses. Has the time come?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

In vivo selection of protease cleavage sites from retrovirus display libraries

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Virus-Receptor Interaction in an Adenovirus System

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Infectious entry pathway of adenovirus type 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Stepwise dismantling of adenovirus 2 during entry into cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Targeted gene delivery by tropism-modified adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Expression of fibroblast growth factors and their receptors in acquired immunodeficiency syndrome-associated Kaposi sarcoma tissue and derived cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Targeted adenoviral vectors for cancer gene therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Organ targeting in vivo using phage display peptide libraries

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Targeted integration of adeno-associated virus-derived plasmids in transfected human cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Cell-specific targeting of a thymidine kinase/ganciclovir gene therapy system using a recombinant Sindbis virus vector

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

High-level expression of the rat whey acidic protein gene is mediated by elements in the promoter and 3' untranslated region

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

GFAP promoter directs astrocyte-specific expression in transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Cellular promoters incorporated into the adenovirus genome: cell specificity of albumin and immunoglobulin expression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Potential for H-DNA in the human MUC1 mucin gene promoter

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Spatial and temporal control of gene therapy using ionizing radiation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Targeting gene expression to hypoxic tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Replicating vectors for gene therapy of cancer: risks, limitations and prospects.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Treatment of human cancer with mumps virus

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Studies on the use of viruses in the treatment of carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

The use of herpes simplex virus-based vectors for gene delivery to the nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Transcriptional targeting of herpes simplex virus for cell-specific replication

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Reovirus therapy of tumors with activated Ras pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Gene therapy death prompts review of adenovirus vector

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900103-2

7 January 2021

10.1016/S1040-8428(01)00103-2

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11369253